Launch Readiness

A Commercial Readiness Checklist for a Biotech Company's First Product Launch

9 August 2026 · Joseph McCoy · Founder & Principal Consultant · PharmaKonsult

A first product launch is a company transformation. Leadership should evaluate readiness across market understanding, access, organization, governance and execution.

Key Takeaways

  • A first launch requires the company itself to become commercially capable—not only promotional readiness.
  • If departments describe the patient journey differently, commercial alignment is incomplete.
  • Coverage should not be confused with access; organization and governance determine whether plans can execute.
  • Readiness is about identifying the greatest risks while leadership still has time to act.

A first product launch represents a fundamental transformation for an emerging biotechnology company.

Success requires far more than preparing promotional materials and recruiting a sales team. The company itself must become commercially capable.

Leadership should evaluate readiness across eight areas. For a structured engagement, see PharmaKonsult’s biotech launch readiness assessment.

Executive opinion paper

Full article

Full article available by request only.

Contact PharmaKonsult to request the complete opinion paper.

About Joseph McCoy

Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and brings 36 years of biopharmaceutical commercial leadership across rare disease and specialty therapeutics, including neuroscience, endocrinology, institutional healthcare and complex treatment markets.

His work focuses on the strategic decisions connecting drug development, commercialization, organizational capability, market access and launch execution.

Share this article